Phase 2
Completed N=13
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Source: ClinicalTrials.gov NCT00639002 ↗Enrolled (actual)
13
Serious AEs
60.0%
Results posted
Jan 2012
Primary outcomePrimary: Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma — 0 participants
Summary
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma |
— | — |
| SECONDARY Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma |
— | — |
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of multiple myeloma with evidence of measurable disease.
- Relapsed or refractory disease with at least one line of prior therapy.
- Adequate bone marrow reserve.
Exclusion Criteria
- Received anti-cancer medications or investigational therapy in the past 28 days.
- Intracranial disease or epidural disease.
Data sourced from ClinicalTrials.gov (NCT00639002). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.